Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1114 - Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes

    Primary Author / Presenter(s)

  • JM

    Jitka Malcikova, PhD

    1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University
    Brno, Czech Republic

    • Co-Author(s)

  • KP

    Karla Plevova

    junior researcher
    Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • VN

    Veronika Navrkalova, PhD

    researcher
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • AP

    Anna Panovská, MD, PhD

    Assistant professor
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • TA

    Tomas Arpas, MD

    Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
    Brno, Czech Republic

  • AP

    Adela Prchlíková, MD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • YB

    Yvona Brychtova, MD, PhD

    Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
    Brno, Czech Republic

  • KT

    Kristýna Taušová, MSc

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • EZ

    Eva Zapletalová, PhD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • JP

    Jakub Porc, MSc

    Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • EO

    Eva Ondroušková, PhD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • BD

    Barbara Dvořáčková, PhD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • JK

    Jana Kopecna, MSc

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • NK

    Natálie Kazdová, MSc

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • MZ

    Marcela Zenatova, MSc

    Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
    Brno, Czech Republic

  • P

    Šárka Pospíšilová, PhD

    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University
    Brno, Jihomoravsky kraj, Czech Republic

  • Michael Doubek, MD, PhD

    Department head
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
    Brno, Jihomoravsky kraj, Czech Republic

  • SP

    Sarka Pavlova, PhD

    senior scientist
    1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University,
    Brno, Czech Republic